RBC Capital maintains Ryan Specialty Holdings at Outperform, lowers price target to $52 from $55

RBC Capital kept Ryan Specialty Holdings at Outperform but reduced its price target to $52 from $55, a 5.5% cut. This implies a 20.1% upside from the Oct 29 close of $43.28. Other recent analyst targets for the company range from $40 to $41.

Original reporting
Published Oct 30, 2026, 5:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 5:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RBC Capital maintains Ryan Specialty Holdings at Outperform, lowers price target to $52 from $55 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The target reduction may prompt short‑term selling pressure, though the rating remains positive.

02

Market read

A modest analyst downgrade with a lower price target, limited trading relevance.

03

What to watch

The article does not discuss underlying business performance or recent earnings, which could mitigate the impact of the target change.

Relevance 4/10Novelty 2/10Timing: today

Background

RBC Capital maintains an Outperform rating but reduces its price target for Ryan Specialty Holdings.

Market effects

Minimal impact on the specialty insurance sector; only reflects one analyst's view.

Limited to U.S. markets where the stock trades.

Low; no broader macro or sector catalyst.

Counterpoint

Some investors may view the target cut as an overreaction if recent earnings were strong.

Key entities

  • Ryan Specialty Holdings

    Specialty insurance provider listed on NYSE under ticker RYAM.

  • RBC Capital

    Equity research firm providing the rating and price target.

Related articles

$RYANMed

Ryan Specialty Holdings Inc (RYAN) (Q3 2026) Earnings Call Highlights: Revenue Growth

Ryan Specialty Holdings (RYAN) reported Q3 2026 revenue growth slowing to 4% from 15% YoY, with adjusted EBITDAC margin down 30 bps to 30.9%. The company cited market challenges, including property pricing declines and increased competition. Management expects continued pressure in Q4 2026 and 2027, with modest margin expansion anticipated. They also discussed growth opportunities in reinsurance and AI-related risks, and potential M&A activity in 2027.

Med

Ryan Specialty grows revenue as property softening squeezes E&S returns

Ryan Specialty reported a 4.7% revenue increase to $790M in Q3 2026, driven by casualty lines, while property revenue declined. Underwriting management grew 5.4%, expanding its share of total revenue. Expenses rose 9.9%, outpacing revenue growth. The company maintained its full-year guidance for mid-single-digit organic revenue growth and reported a 3.8% increase in adjusted EBITDAC to $244.4M.